Robert Driscoll
Stock Analyst at Wedbush
(3.08)
# 1,205
Out of 5,147 analysts
163
Total ratings
39.58%
Success rate
2.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Underperform | $7 | $13.78 | -49.20% | 1 | Feb 26, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Outperform | $29 → $30 | $10.60 | +183.02% | 7 | Feb 25, 2026 | |
| ARVN Arvinas | Maintains: Neutral | $9 → $11 | $13.27 | -17.11% | 10 | Feb 25, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $49 → $52 | $32.20 | +61.49% | 10 | Feb 18, 2026 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $37 → $53 | $33.31 | +59.11% | 10 | Feb 13, 2026 | |
| APRE Aprea Therapeutics | Maintains: Outperform | $11 → $7 | $0.92 | +663.61% | 4 | Feb 10, 2026 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $19 | $7.65 | +148.37% | 8 | Feb 4, 2026 | |
| CGON CG Oncology | Initiates: Outperform | $70 | $58.80 | +19.05% | 1 | Dec 11, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $25 → $34 | $15.50 | +119.35% | 5 | Dec 9, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $8.73 | +335.28% | 11 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $77 → $80 | $102.02 | -21.58% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $8.57 | +343.41% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $12.09 | +123.33% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $2.39 | +67.36% | 11 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $6 | $0.60 | +899.67% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $17.75 | -4.23% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.47 | +547.77% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $20.37 | +47.28% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $7.25 | +1,003.45% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.68 | +128.87% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $11.14 | +16.70% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $13.61 | +443.72% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.65 | +41.59% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.68 | +316.67% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $5.37 | +48.98% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.66 | -14.16% | 4 | May 19, 2020 |
Eikon Therapeutics
Feb 26, 2026
Initiates: Underperform
Price Target: $7
Current: $13.78
Upside: -49.20%
Day One Biopharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $29 → $30
Current: $10.60
Upside: +183.02%
Arvinas
Feb 25, 2026
Maintains: Neutral
Price Target: $9 → $11
Current: $13.27
Upside: -17.11%
IDEAYA Biosciences
Feb 18, 2026
Maintains: Outperform
Price Target: $49 → $52
Current: $32.20
Upside: +61.49%
Tyra Biosciences
Feb 13, 2026
Maintains: Outperform
Price Target: $37 → $53
Current: $33.31
Upside: +59.11%
Aprea Therapeutics
Feb 10, 2026
Maintains: Outperform
Price Target: $11 → $7
Current: $0.92
Upside: +663.61%
Replimune Group
Feb 4, 2026
Maintains: Outperform
Price Target: $18 → $19
Current: $7.65
Upside: +148.37%
CG Oncology
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $58.80
Upside: +19.05%
Cullinan Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $25 → $34
Current: $15.50
Upside: +119.35%
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $8.73
Upside: +335.28%
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $102.02
Upside: -21.58%
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $8.57
Upside: +343.41%
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $12.09
Upside: +123.33%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.39
Upside: +67.36%
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.60
Upside: +899.67%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $17.75
Upside: -4.23%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.47
Upside: +547.77%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $20.37
Upside: +47.28%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $7.25
Upside: +1,003.45%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.68
Upside: +128.87%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $11.14
Upside: +16.70%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $13.61
Upside: +443.72%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.65
Upside: +41.59%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.68
Upside: +316.67%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $5.37
Upside: +48.98%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.66
Upside: -14.16%